SHANDONG XINHUA (00719): Abnormal Fluctuations in A-share Trading; There Is No Need to Correct or Supplement Previously Disclosed Information

SHANDONG XINHUA (00719) issued an announcement that the A-share stock of SHANDONG XINHUA Co., Ltd. (the "Company") had a cumulative deviation of 20% in closing price increases over three consecutive trading days on September 18, September 21, and September 22, 2026. According to the relevant provisions of the Shenzhen Stock Exchange, this constitutes an abnormal fluctuation in stock trading. In response to the abnormal fluctuation of the Company's stock, the Company has verified the relevant matters, and the relevant circumstances are explained as follows: 1. Upon verification, there is no need to correct or supplement the information previously disclosed by the Company. 2. The Company has not found any undisclosed material information in recent public media reports that may or has already had a significant impact on the Company's stock trading price. 3. There have been no major changes in the Company's recent operating conditions and internal and external operating environment. 4. On September 21, 2026, the Company disclosed the "Announcement on Obtaining the Drug Registration Certificate for Sodium Magnesium Potassium Sulfate Oral Concentrated Solution," the "Announcement on the Subsidiary Obtaining the Drug Registration Certificate for Donepezil Hydrochloride Orally Disintegrating Tablets," and the "Announcement on Obtaining the Drug Registration Certificate for Levocarnitine Oral Solution." 5. On September 1, 2026, the Company disclosed the "Announcement on Azithromycin Tablets Passing the Generic Drug Consistency Evaluation." 6. The Company has not found any other major information requiring disclosure that may have a significant impact on the Company's stock price. 7. Upon inquiry to the Company's controlling shareholder and actual controller, there are no major matters concerning the Company that should be disclosed but have not been disclosed, or major matters in the planning stage. 8. Upon inquiry, the controlling shareholder and actual controller did not buy or sell the Company's stock during the period of abnormal fluctuation of the Company's stock trading.